2:00 pm - 3:45 pm EDT
This teleseminar is available for purchase through our audio/video provider Playback Now. Please call 800.241.7785 or
visit http://www.playbackaaj.com/ to place your order.
Presented with AAJ’s Risperdal Litigation Group.
Join AAJ Education and a faculty of experienced trial lawyers for a webinar on Risperdal, an antipsychotic drug manufactured by Johnson & Johnson which has been linked to gynecomastia among adolescent males.
This in-depth plaintiffs-only webinar will cover key topics concerning the off-label and failure to warn claims against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. The faculty will also cover the latest trends and updates in Risperdal litigation, including FDA Approvals, Indications, medical literature, the Johnson & Johnson Sponsored Clinical Trials, Labeling and Liability; the science behind the drug and causations for gynecomastia; experts; and potential damages.
Open only to AAJ Plaintiff Members (Regular, Life, Sustaining, President’s Club, and Leaders Forum) and AAJ Paralegal Affiliates.
Robert Mosier, CA
FDA Approvals, Indications, Labeling, & Liability
• AG Settlements/Verdicts
Claudine Homolash, PA
Science & Causations
Christopher Gomez, PA
Amy M. Carter, TX
Victoria J. Maniatis, NY
Question and Answer Session
Contribute to the AAJ Education Fund
Please consider a donation to the AAJ Education Fund 501(c)(3). Contributions support educational programs and activities to preserve and protect the civil justice system.
Learn more »